Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet the Migraine diagnosis.~* Age of onset should be before age 50 years.~* Migraine must have been occurring for 1 year preceding entry into the trial.~* The number of migraine attack should be no less than 6 for a period of 3 months prior to Screening stage.~* The number of migraine days is to be 2-8 for a period of 1 month prior to screening for entry into the trial.~* Migraine days should be less than 15 for a period of 1 month prior to screening for entry into the trial.~* Ages 18-65.~* Participant can understand and complete the Headache diary.~* All participants signed the informed consent.~Exclusion Criteria:~* Other migraine prophylactic medication is continued 3 months prior to the drug trial.~* Participants who have taken Tianshu capsule during 1 month prior to Screening stage.~* The number of acute treatment for migraine is more than 10 per month.~* Participants who have taken antipsychotics or antidepressant medications (unless only for migraine prophylaxis) during the previous 3 months.~* Participants who abuse alcohol or other drugs.~* Participants who are resistant to all acute migraine drugs prescribed optimally.~* hypotension or uncontrolled hypertension.~* Severe infections.~* Malignancy.~* Significant medical history of such as cardiac disease, cerebrovascular disease, liver disease, nephropathy etc.~* Known allergies or serious side effects with Tianshu capsule in the past.~* Breastfeeding, pregnant and potentially fertile women participant.~* History of cluster headaches, tension-type headache, vascular headache with non-migraine, drug - dependence headache.~* Secondary headaches, including hypertension, post-traumatic brain syndrome etc.~* Participants who have taken migraine prophylactic medication regularly during 1 month prior to Screening stage.~* Participants who are taking part in other clinical trials.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tianshu capsule (Type: EXPERIMENTAL): Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
- Sugar pill (Type: PLACEBO_COMPARATOR): Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).